Success Metrics

Active Trials
6(100%)

Phase Distribution

Ph phase_1
5
83%
Ph phase_2
1
17%

Phase Distribution

5

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
5(83.3%)
Phase 2Efficacy & side effects
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

6

all time

Status Distribution
Active(6)

Detailed Status

Recruiting4
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
6
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 15 (83.3%)
Phase 21 (16.7%)

Trials by Status

active_not_recruiting233%
recruiting467%

Recent Activity

6 active trials
Showing 5 of 6
recruitingphase_1

A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

NCT06887803
recruitingphase_1

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

NCT07203391
recruitingphase_1

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

NCT06644183
recruitingphase_1

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

NCT07018752
active_not_recruitingphase_2

A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

NCT06717126
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06887803Phase 1

A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

Recruiting
NCT07203391Phase 1

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

Recruiting
NCT06644183Phase 1

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Recruiting
NCT07018752Phase 1

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

Recruiting
NCT06717126Phase 2

A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

Active Not Recruiting
NCT06879717Phase 1

A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients

Active Not Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6